KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other financing activities (2016 - 2023)

Historic Other financing activities for Ionis Pharmaceuticals (IONS) over the last 8 years, with Q3 2023 value amounting to $517000.0.

  • Ionis Pharmaceuticals' Other financing activities fell 1972.05% to $517000.0 in Q3 2023 from the same period last year, while for Dec 2024 it was $517000.0, marking a year-over-year decrease of 7274.64%. This contributed to the annual value of $14.2 million for FY2023, which is 2941.66% up from last year.
  • Ionis Pharmaceuticals' Other financing activities amounted to $517000.0 in Q3 2023, which was down 1972.05% from $736000.0 recorded in Q4 2022.
  • Ionis Pharmaceuticals' Other financing activities' 5-year high stood at $15.3 million during Q1 2021, with a 5-year trough of $367000.0 in Q2 2020.
  • For the 5-year period, Ionis Pharmaceuticals' Other financing activities averaged around $3.6 million, with its median value being $517000.0 (2023).
  • Its Other financing activities has fluctuated over the past 5 years, first soared by 158447.89% in 2019, then tumbled by 9083.67% in 2020.
  • Over the past 5 years, Ionis Pharmaceuticals' Other financing activities (Quarter) stood at $401000.0 in 2019, then rose by 12.22% to $450000.0 in 2020, then dropped by 2.22% to $440000.0 in 2021, then surged by 67.27% to $736000.0 in 2022, then decreased by 29.76% to $517000.0 in 2023.
  • Its Other financing activities was $517000.0 in Q3 2023, compared to $736000.0 in Q4 2022 and $644000.0 in Q3 2022.